Fevziye TOROS, Ayşegül Yolga TAHİROĞLU, ÖZGE METİN, Canan Kuygun KARCİ

Effects of Methylphenidate Treatment on Quality of Life in Adolescents

Ergenlerde metilfenidat tedavisinin yaşam kalitesi üzerine etkisiAmaç: Dikkat eksikliği hiperaktivite bozukluğu (DEHB) çocukluk çağında en sık görülen ruhsal bozukluklardan birisidir. Yaşam kalitesini bozan süreğen bir bozukluk olan DEHB'nin tedavisi ile yaşam kalitesinde iyileşme gözlenmektedir. Bu çalışmada metilfenidat tedavisi ile ergenin yaşam kalitesindeki ve DEHB'ye sıklıkla eşlik eden kaygı ve depresyon belirtilerindeki değişikliklerin incelenmesi amaçlanmıştır. Yöntem: Mersin Üniversitesi Tıp Fakültesi Hastanesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Polikliniğine başvuran hastalardan DEHB tanısı almış 13-18 yaş arası, ilk kez metilfenidat başlanmış ve 3 ay tedavisi devam etmiş olan 50 olgu çalışmaya dahil edildi. Olguların arşiv dosyaları taranarak tedavi öncesinde ve 3 ay sonrasında uygulanan Çocuklar İçin Depresyon Ölçeği (ÇİDÖ), Çocuklar İçin Sürekli Kaygı Ölçeği (ÇİSKÖ), Pediyatrik Yaşam Kalitesi EnvanteriTM (PedYKTM 4.0) ergen ve ebeveyn formları değerlendirildi.Bulgular: Metilfenidat tedavisi sonucunda fiziksel işlevsellik puanı hariç yaşam kalitesi puanlarında yükselme gözlendi. Ergen ve ebeveyn formu karşılaştırıldığında, ergen formunda yaşam kalitesi puanlarının daha yüksek olduğu saptandı. Tedavi öncesinde ve sonrasında erkek ergenlerin kızlara kıyasla yaşam kalitesini daha olumlu puanladıkları gözlendi. Aynı zamanda, metilfenidat tedavisi ile kaygı belirtilerinde de iyileşme olduğu gözlendi.Sonuç: DEHB'nin tedavisi ile yaşam kalitesindeki değişiklikleri saptamak, DEHB tedavisinin önemini vurgulamak, tedavi sonuçlarını değerlendirmek ve etkin, çok yönlü tedavi planları oluşturmak açısından önemli bir yer tutmaktadır

Ergenlerde metilfenidat tedavisinin yaşam kalitesi üzerine etkis

Effects of methylphenidate treatment on quality of life in adolescentsObjective: Attention-deficit hyperactivity disorder (ADHD) is one of the most common childhood mental disorders. Improvement in quality of life is observed with the treatment of ADHD which is a chronic disorder that disrupts the quality of life. In this study, it was aimed to investigate the changes in symptoms of anxiety and depression associated with ADHD and quality of life of adolescents after methylphenidate treatment.Method: Fifty patients between 13-18 years old, who admitted to Mersin University Medical Faculty Hospital Pediatric and Adolescent Psychiatry Outpatient Clinics; were diagnosed with ADHD; received methylphenidate treatment for the first time; and continued with the treatment for three months; were included in the study. Pretreatment and 3rd month results of Children’s Depression Inventory (CDI), StateTrait Anxiety Inventory for Children (STAI-CH), and adolescent and parent forms of Pediatric Quality of Life InventoryTM 4.0 (PedsQLTM 4.0) were assessed by retrospectively screening of patient charts. Results: After methylphenidate treatment, quality of life scores were improved, except for physical functioning. Quality of life scores were higher in adolescent reports, compared to parents. Male adolescents scored their quality of life more positively than girls before and after the treatment. In addition, anxiety symptoms improved after methylphenidate treatment.Conclusion: It is important to determine the changes in quality of life with the treatment of ADHD in terms of emphasizing the importance of ADHD treatment, evaluating treatment outcomes, and establishing effective and sophisticated treatment plans

PDF

___

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Fourth Ed. Washington, DC: American Psychiatric Association, 1994.
2. Floet AM, Scheiner C, Grossman L. Attention-deficit/ hyperactivity disorder. Pediatr Rev 2010; 31:56-69. [CrossRef]
3. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011; 20:17-37. [CrossRef]
4. Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J; ADHD European Guidelines Group. Practitioner review: quality of life in child mental health—conceptual challenges and practical choices. J Child Psychol Psychiatry 2009; 50:544-561. [CrossRef]
5. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Zuddas A, Coghill D. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010; 19:83- 105. [CrossRef]
6. Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002; 41:530-537. [CrossRef]
7. Bastiaansen D, Koot HM, Ferdinand RF, Verhulst FC. Quality of life in children with psychiatric disorders: self-, parent, and clinician report. J Am Acad Child Adolesc Psychiatry 2004; 43:221-230. [CrossRef]
8. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25:166-174. [CrossRef]
9. Yang P, Hsu HY, Chiou SS, Chao MC. Health-related quality of life in methylphenidate-treated children with attention-deficithyperactivity disorder: results from a Taiwanese sample. Aust N Z J Psychiatry 2007; 41:998-1004. [CrossRef]
10. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention deficit/hyperactivity disorder. Pediatrics 2004; 114:e541-547. [CrossRef]
11. Ozusta S. Turkish standardization, reliability and validity of State-Trait Anxiety Inventory for Children. Turkish Journal of Psychology 1995; 10:32-44. (Turkish)
12. Oy B, Ilgen R, Ekmekci A, Turkmen M, Yilmaz N, Basoglu N. Application of State-Trait Anxiety Inventory for children to primary and secondary school children. Turk J Child Adolesc Ment Health 1995; 2:76-81. (Turkish)
13. Kovacs M. Rating scale to assess depression in school aged children. Acta Paedopsychiatr 1981; 46:305-315.
14. Oy B. Reliability and validity of Children’s Depression Inventory. Turk J Psych 1991; 2:132-136. (Turkish)
15. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37:126-139. [CrossRef]
16. Cakin-Memik N, Agaoglu B, Coskun A, Uneri OS, Karakaya I. The validity and reliability of the Turkish pediatric quality of life inventory for children 13-18 years old. Turk Psikiyatri Derg 2007; 18:353-363. (Turkish)
17. Eiser, C, Morse R. Can parents rate their child’s health-related quality of life? Results of a systematic review. Qual Life Res 2001; 10:347-357. [CrossRef]
18. Upton, P, Lawford, J, Eiser, C. Parent–child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res 2008; 17:895-913. [CrossRef]
19. Coghill, D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs 2010; 24:843-866.
20. Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health 2010; 46:209-217. [CrossRef]
21. Lee YC, Yang HJ, Chen VC, Lee WT, Teng MJ, Lin CH, Gossop M. Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL™. Res Dev Disabil 2016; 51-52:160-172. [CrossRef]
22. Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 2004; 25:264-271. [CrossRef]
23. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attentiondeficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:240-248. [CrossRef]
24. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group. A multi-centre, randomised, openlabel study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/ hyperactivity disorder (ADHD). Curr Med Res Opin 2007; 23:379-394. [CrossRef]
25. Flapper BC, Schoemaker MM. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Dev Med Child Neurol 2008; 50:294-299. [CrossRef]
26. Gurkan K, Bilgic A, Turkoglu S, Kilic BG, Aysev A, Uslu R. Depression, anxiety and obsessive–compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol 2010; 24:1810-1818. [CrossRef]
27. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13(Suppl.1):I102-116. [CrossRef]
28. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 2008; 69:131-140. [CrossRef]
29. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45:1284-1293. [CrossRef]
30. Coghill D, Hodgkins P. Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. Eur Child Adolesc Psychiatry 2016; 25:261-271. [CrossRef]
31. Radziuk AL, Kieling RR, Santos K, Rotert R, Bastos F, Palmini AL. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav 2015; 46:215-220. [CrossRef]
32. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/ hyperactivity disorder: a population-based study. Health Qual Life Outcomes 2006; 4:26. [CrossRef]
33. Yurumez E, Kilic BG. Relationship between sleep problems and quality of life in children with ADHD. J Atten Disord 2016; 20:34-40. [CrossRef]
34. Limbers CA, Ripperger-Suhler J, Heffer RW, Varni JW. Patientreported Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales in pediatric patients with attention-deficit/hyperactivity disorder and comorbid psychiatric disorders: feasibility, reliability, and validity. Value Health 2011; 14:521-530. [CrossRef]
35. Limbers CA, Ripperger-Suhler J, Boutton K, Ransom D, Varni JW. A comparative analysis of health-related quality of life and family impact between children with ADHD treated in a general pediatric clinic and a psychiatric clinic utilizing the PedsQL. J Atten Disord 2011; 15:392-402. [CrossRef]
36. Jafari P, Ghanizadeh A, Akhondzadeh S, Mohammadi MR. Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Qual Life Res 2011; 20:31-36. [CrossRef]
37. Kolsteren MM, Koopman HM, Schalekamp G, Mearin ML. Health-related quality of life in children with celiac disease. J Pediatr 2001; 138:593-595. [CrossRef]
38. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39:800-812. [CrossRef]
39. Owens JS, Goldfine ME, Evangelista NM, Hoza B, Kaiser NM. A critical review of self-perceptions and the positive illusory bias in children with ADHD. Clin Child Fam Psychol Rev 2007; 10:335- 351. [CrossRef]
40. Uneri O. Cakin Memik N. Concept of quality of life in children and review of inventories about quality of life. Turk J Child Adolesc Ment Health 2007; 14:48-56. [CrossRef] (Turkish)
41. Velő S, Kereszteny A, Szentivanyi D, Balazs J. Quality of life of patients with attention-deficit/hyperactivity disorder: systematic review of the past 5 years. Neuropsychopharmacol Hung 2013; 15:73-82. (Hungarian)
42. Dallos G, Miklósi M, Keresztény Á, Velő S, Szentiványi D, Gádoros J, Balázs J. Self-and parent-rated quality of life of a treatment naïve sample of children with adhd the impact of age, gender, type of ADHD, and comorbid psychiatric conditions according to both a categorical and a dimensional approach. J Atten Disord 2017; 21:721-730. [CrossRef]
43. Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin 2009; 25:3001-3010. [CrossRef]
44. Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSM-IV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry 2001; 40:1410-1417. [CrossRef]
45. Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2014; (9):CD005041. [CrossRef]
46. Goez H, Back-Bennet O, Zelnik N. Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder. J Child Neurol 2007; 22:538-542. [CrossRef]
47. Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2015; 25:611-617. [CrossRef]
48. Segev A, Gvirts HZ, Strouse K, Mayseless N, Gelbard H, Lewis YD, Barnea Y, Feffer K, Shamay-Tsoory SG, Bloch Y. A possible effect of methylphenidate on state anxiety: a single dose, placebo controlled, crossover study in a control group. Psychiatry Res 2016; 241:232-235. [CrossRef]
49. Snircova E, Marcincakova-Husarova V, Hrtanek I, Kulhan T, Ondrejka I, Nosalova G. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD. Pediatr Int 2016; 58:476-481. [CrossRef]
50. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68:93-101. [CrossRef]
51. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomized, placebo controlled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259:120-129. [CrossRef]
52. Cussen A, Sciberras E, Ukoumunne OC, Efron D. Relationship between symptoms of attention-deficit/hyperactivity disorder and family functioning: a community-based study. Eur J Pediatr 2012; 171:271-280. [CrossRef]